Chengdu Easton Biopharmaceuticals (688513.SH): Two types of improved new drugs, acetaminophen hydroxypropanone sustained-release tablets, have obtained drug registration certificates.

Chengdu Easton Biopharmaceuticals (688513.SH) announced that the company recently received the "Drug Registration Certificate" for the approved and issued Amfenac Hydrocodone Controlled-release Tablets from the National Medical Products Administration. The indication for the company's Amfenac Hydrocodone Controlled-release Tablets is for the treatment of postoperative moderate to severe pain in patients who cannot tolerate alternative treatments (such as non-opioid medications) or when alternative treatments cannot meet the analgesic needs and opioid medications are needed. This product is an improvement based on the company's proprietary controlled-release formulation technology platform, using a dual-layer design with a fast-release layer and sustained-release layer for quick onset of action and 12-hour long-lasting and steady pain relief, avoiding the need for nighttime dosing, ensuring sleep quality, and improving patient compliance. Its physical barrier technology effectively prevents the abuse of opioid medications.